Plain-English translation of NCT06727630 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage trial testing a new medication called in people with advanced melanoma that cannot be surgically removed or has spread to other parts of the body. The medication is a type of drug that works by blocking a specific protein involved in cancer growth. This trial will help doctors understand the right dose, how safe it is, and whether it actually helps fight the cancer.
Current treatments don't work well for all melanoma patients, and some people's cancer stops responding over time. Researchers developed this medication as a new approach and now need to test it in humans to see if it could offer another treatment option.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth once daily, starting at the lowest planned dose (300 mg per day). Researchers will gradually increase the dose in small groups of patients to find the safest and most effective amount. You'll need to track your daily doses and attend clinic visits for blood tests, imaging scans, and check-ups so doctors can watch for side effects and see if the treatment is working. The trial aims to enroll about 40 people in China.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Zhuhai Yufan Biotechnologies Co., Ltd
Enrollment target
~40 participants
Started
March 2024
Primary completion
April 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Liting Lai, Bachelor
VP
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.